PrescriptionDrug-Info.com - The People's Medicine Community

Vilazodone




Vilazodone
Systematic (IUPAC) name
5-(4-[4-(5-cyano-1H-indol-3-yl)butyl]piperazin-1-yl)benzofuran-2-carboxamide
Clinical data
Trade names Viibryd
AHFS/Drugs.com Consumer Drug Information
MedlinePlus a611020
Licence data US FDA:link
Pregnancy cat. C (US)
Legal status -only (US)
Routes Oral
Pharmacokinetic data
Half-life 20-24 hours
Identifiers
CAS number 163521-12-8 N
ATC code N06AX24
PubChem CID 6918313
ChemSpider 5293518 YesY
UNII S239O2OOV3 YesY
KEGG D09698 YesY
ChEBI CHEBI:70707 YesY
ChEMBL CHEMBL439849 YesY
Chemical data
Formula C26H27N5O2 
Mol. mass 441.524 g/mol
 N (what is this?)  (verify)

Vilazodone (United States trade name Viibryd) is a serotonergic antidepressant developed by Clinical Data for the treatment of major depressive disorder. The chemical compound was originally developed by Merck KGaA (Germany).[1] By 2009 two phase III clinical trials with positive results had been completed.[2] Vilazodone was approved by the FDA for use in the United States to treat major depressive disorder on January 21, 2011.[3][4][5]


Contents

  • 1 Pharmacology
  • 2 Efficacy and tolerability
  • 3 See also
  • 4 References

Pharmacology

Vilazodone acts as a serotonin reuptake inhibitor (IC50 = 0.5 nM) and 5-HT1A receptor partial agonist (IC50 = 0.2 nM; IA = ~60-70%).[6][7] It has negligible affinity for other serotonin receptors such as 5-HT1D, 5-HT2A, and 5-HT2C.[6][7]

Partial agonism of the 5-HT1A receptor is a relatively novel mechanism of action and is also shared by the anxiolytic buspirone (Buspar), and the atypical antipsychotic / antidepressant aripiprazole (Abilify).


Efficacy and tolerability

Vilazodone is approved in 10 mg, 20 mg, and 40 mg doses.

According to two eight-week, randomized, double-blind, placebo-controlled trials in adults, vilazodone was reported to elicit an antidepressant response after one week of treatment. After eight weeks, subjects assigned to vilazodone 40mg daily dose (titrated over 2 weeks) experienced a significantly higher response rate than the group given placebo (44% vs 30%, P = .002). But, remission rates for vilazodone were not significantly different versus placebo. [8][9] After a 1 year, open-label study assessing the safety and tolerability of vilazodone in patients with major depressive disorder, the most common adverse effects were diarrhea (35.7%), nausea (31.6%), and headache (20.0%); greater than 90% of these AEs were mild or moderate.[10] In contrast to other SSRIs currently on the market, initial clinical trials showed that vilazodone did not cause significant weight gain or decreased sexual desire/function as with many other antidepressants, which often cause people to abandon their use.[3]

However, FDA staff called these claims into question in a September 2011 article that concluded "it is unknown whether [vilazodone] has any advantages compared to other drugs in the antidepressant class." [11]


See also

  • Etoperidone
  • Nefazodone
  • Trazodone
  • Vortioxetine

References

  1. ^ Clinical Data's Vilazodone Patient Enrollment Over One Third Complete. August 17th, 2006[dead link]
  2. ^ de Paulis T (March 2007). "Drug evaluation: Vilazodone--a combined SSRI and 5-HT1A partial agonist for the treatment of depression". IDrugs : the Investigational Drugs Journal 10 (3): 193-201. PMID 17351874. 
  3. ^ a b "FDA approves Clinical Data Inc's antidepressant". Reuters. January 22, 2011. 
  4. ^ "FDA approves Clinical Data Inc's antidepressant". Reuters. January 22, 2011. 
  5. ^ "Clinical Data, Inc. - Clinical Data, Inc. Submits New Drug Application for Vilazodone for the Treatment of Major Depressive Disorder". 
  6. ^ a b Page ME, Cryan JF, Sullivan A, et al. (September 2002). "Behavioral and neurochemical effects of 5-(4-[4-(5-Cyano-3-indolyl)-butyl)-butyl]-1-piperazinyl)-benzofuran-2-carboxamide (EMD 68843): a combined selective inhibitor of serotonin reuptake and 5-hydroxytryptamine(1A) receptor partial agonist". The Journal of Pharmacology and Experimental Therapeutics 302 (3): 1220-7. doi:10.1124/jpet.102.034280. PMID 12183683. 
  7. ^ a b Hughes ZA, Starr KR, Langmead CJ, et al. (March 2005). "Neurochemical evaluation of the novel 5-HT1A receptor partial agonist/serotonin reuptake inhibitor, vilazodone". European Journal of Pharmacology 510 (1-2): 49-57. doi:10.1016/j.ejphar.2005.01.018. PMID 15740724. 
  8. ^ Rickels K, Athanasiou M, Robinson DS, Gibertini M, Whalen H, Reed CR (March 2009). "Evidence for efficacy and tolerability of vilazodone in the treatment of major depressive disorder: a randomized, double-blind, placebo-controlled trial". The Journal of Clinical Psychiatry 70 (3): 326-33. PMID 19284933. 
  9. ^ USA (2013-01-30). "A randomized, double-blind, placebo-controlled, 8-week study of vilazodone, a serotonergic agent for the treatment of major depressive disorder". Ncbi.nlm.nih.gov. Retrieved 2013-02-28. 
  10. ^ USA (2013-01-30). "A 1-year, open-label study assessing the safety and tolerability of vilazodone in patients with major depressive disorder". Ncbi.nlm.nih.gov. Retrieved 2013-02-28. 
  11. ^ Laughren TP, Gobburu J, Temple RJ, Unger EF, Bhattaram A, Dinh PV, Fossom L, Hung HM, Klimek V, Lee JE, Levin RL, Lindberg CY, Mathis M, Rosloff BN, Wang SJ, Wang Y, Yang P, Yu B, Zhang H, Zhang L, Zineh I (September 2011). "Vilazodone: clinical basis for the US Food and Drug Administration's approval of a new antidepressant". The Journal of Clinical Psychiatry 72 (9): 1166-73. PMID 21951984. 




The above article is from Wikipedia.
All text is available under the terms of the GFDL (GNU Free Documentation License)
http://en.wikipedia.org/wiki/Vilazodone

Note: All times displayed are UTC - 7



This information has been independently compiled and is for educational purposes only. It is not intended to be a substitute for face to face medical advice from a qualified healthcare professional. It is also not intended to diagnose, treat, or prevent any medical condition. Please remember that all of the content within this community is compiled by the users of this site. Our website displays many pages which do not contain any medical information regarding the drug name stated. These pages are only provided for the purpose of opening community discussions about that drug by our users. For more details please see the Disclaimer. This data is Copyright © 2005-2013 PrescriptionDrug-Info.com and is protected under U.S. and International Copyright laws. All Rights Reserved. This page was last updated on 13 March 2013.

We are committed to your privacy.

TRUSTe online privacy certification
IAB Member
Ad Choices
Support Wikipedia
Valid HTML5
Copyright © 2005-2013 PrescriptionDrug-Info.com. All Rights Reserved.